Angio-OCT引导IQ577TMIRIDEX微脉冲激光联合抗新生血管药物治疗糖尿病性黄斑水肿的临床效果  

Clinical effect of Angio-OCT-guided IQ577TMIRIDEX micropulse laser combined with anti-angiogenesis drugs in the treatment of diabetic macular edema

作　　者：余婧[1] 邱新文[2] 叶波[2] YU Jing;QIU Xinwen;YE Bo(Department of Ophthalmology,People's Hospital of Leping,Jiangxi Province,Leping 333300,China;Department of Ophthalmology,Nanchang Aier Eye Hospital,Jiangxi Province,Nanchang 330000,China)

机构地区：[1]江西省乐平市人民医院眼科,江西乐平333300 [2]南昌爱尔眼科医院眼科,江西南昌330000

出　　处：《中国当代医药》2024年第10期35-39,共5页China Modern Medicine

基　　金：江西省卫生计生委科技计划项目(20197093)。

摘　　要：目的探究Angio-OCT引导IQ577TMIRIDEX微脉冲激光联合抗新生血管药物治疗糖尿病性黄斑水肿的临床效果。方法回顾性分析2019年1月至2021年1月乐平市人民医院眼科收治的60例糖尿病黄斑水肿患者的临床资料,按照不同治疗方案将其分为联合治疗组(30例)与单纯抗血管内皮生长因子(VEGF)组(30例),联合治疗组患者采用Angio-OCT引导IQ577TMIRIDEX微脉冲激光联合抗VEGF药物进行治疗,单纯抗VEGF组采用抗VEGF药物进行玻璃体腔注射治疗,比较两组患者的最佳矫正视力(BCVA)、黄斑中心凹厚度(CMT)、黄斑中心凹无血管区面积(FAZ)、浅层毛细血管丛(SCP)、深层毛细血管丛(DCP)的平均血流密度(VD)的变化,并评估治疗安全性。结果两组患者治疗1、2、3个月时的BCVA均高于本组治疗前,治疗2、3个月时的BCVA均高于治疗1个月时,治疗3个月时的BCVA高于治疗2个月时,差异有统计学意义(P<0.05)。治疗2、3个月时,单纯抗VEGF组的BCVA均低于同时刻联合治疗组,差异有统计学意义(P<0.05)。两组患者治疗1、2、3个月时的CMT均低于本组治疗前,治疗2、3个月时的CMT均低于治疗1个月时,治疗3个月时的CMT低于治疗2个月时,差异有统计学意义(P<0.05)。治疗1、2、3个月时,单纯抗VEGF组的CMT均高于同时刻联合治疗组,差异有统计学意义(P<0.05)。两组患者治疗前后的FAZ、SCP VD、DCP VD比较,差异无统计学意义(P>0.05);两组患者均未出现明显眼部或全身性不良反应。结论在糖尿病黄斑水肿患者的治疗中,采用Angio-OCT引导IQ577TMIRIDEX微脉冲激光联合抗VEGF药物能够有效地改善患者的视力水平,降低黄斑中心凹厚度,提升患者的治疗效果,方法操作简便,安全性较高,值得临床应用与推广。Objective To investigate the clinical effect of Angio-OCT-guided IQ577TMIRIDEX micropulse laser combined with anti-angiogenesis drugs in the treatment of diabetic macular edema.Methods The clinical data of 60 patients with diabetic macular edema admitted to the Department of Ophthalmology,People's Hospital of Leping from January 2019 to January 2021 were retrospectively analyzed.According to different treatment regimens,they were divided into combined treatment group(30 cases)and simple anti-vascular endothelial growth factor(VEGF)group(30 cases).The patients in the combined treatment group were treated with Angio-OCT-guided IQ577TMIRIDEX micropulse laser combined with anti-VEGF drugs,and the patients in the simple anti-VEGF group were treated with intravitreal anti-VEGF drugs.The best corrected visual acuity(BCVA),central macular thickness(CMT),foveal avascular zone(FAZ),mean vessel density(VD)of superficial capillary plexus(SCP)and deep capillary plexus(DCP)were compared between the two groups,and the safety of treatment was evaluated.Results The BCVA at 1,2 and 3 months of treatment in the two groups were higher than those before treatment,the BCVA at 2 and 3 months of treatment in the two groups were higher than those at 1 month of treatment,and the BCVA at 3 months of treatment in the two groups were higher than those at 2 months of treatment,and the differences were statistically significant(P<0.05).After 2 and 3 months of treatment,the BCVA of the simple anti-VEGF group were lower than those of the combined treatment group at the same time,and the differences were statistically significant(P<0.05).The CMT at 1,2 and 3 months of treatment in the two groups were lower than those before treatment,the CMT of the two groups at 2 and 3 months of treatment in the two groups were lower than those at 1 month of treatment,and the CMT at 3 months of treatment in the two groups were lower than those at 2 months of treatment,and the differences were statistically significant(P<0.05).At 1,2 and 3 months after treatment,

关 键 词：糖尿病黄斑水肿 视网膜厚度 最佳矫正视力 黄斑中心凹厚度 视力水平 

分 类 号：R774.5[医药卫生—眼科] R587.2[医药卫生—临床医学]